HomeCompareBVSFF vs MRK

BVSFF vs MRK: Dividend Comparison 2026

BVSFF yields 6.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BVSFF wins by $2.73M in total portfolio value
10 years
BVSFF
BVSFF
● Live price
6.00%
Share price
$1.00
Annual div
$0.06
5Y div CAGR
55%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.79M
Annual income
$1,977,938.28
Full BVSFF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — BVSFF vs MRK

📍 BVSFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVSFFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVSFF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVSFF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVSFF
Annual income on $10K today (after 15% tax)
$510.00/yr
After 10yr DRIP, annual income (after tax)
$1,681,247.54/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, BVSFF beats the other by $1,672,650.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVSFF + MRK for your $10,000?

BVSFF: 50%MRK: 50%
100% MRK50/50100% BVSFF
Portfolio after 10yr
$1.42M
Annual income
$994,026.03/yr
Blended yield
69.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BVSFF
No analyst data
Altman Z
6.7
Piotroski
7/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVSFF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVSFFMRK
Forward yield6.00%2.81%
Annual dividend / share$0.06$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR55%32.7%
Portfolio after 10y$2.79M$57.7K
Annual income after 10y$1,977,938.28$10,113.78
Total dividends collected$2.69M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BVSFF vs MRK ($10,000, DRIP)

YearBVSFF PortfolioBVSFF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,630$930.00$11,213$373.04+$417.00BVSFF
2$14,011$1,566.79$12,667$512.06+$1.3KBVSFF
3$17,726$2,734.29$14,439$708.14+$3.3KBVSFF
4$23,978$5,011.13$16,640$988.16+$7.3KBVSFF
5$35,476$9,819.41$19,432$1,394.07+$16.0KBVSFF
6$59,004$21,045.26$23,057$1,992.90+$35.9KBVSFF
7$113,840$50,705.41$27,889$2,894.79+$86.0KBVSFF
8$263,523$141,714.20$34,518$4,286.29+$229.0KBVSFF
9$757,179$475,209.26$43,912$6,494.35+$713.3KBVSFF
10$2,788,120$1,977,938.28$57,714$10,113.78+$2.73MBVSFF

BVSFF vs MRK: Complete Analysis 2026

BVSFFStock

Bravura Solutions Limited engages in the development, licensing, and maintenance of administration and management software applications for the wealth management and funds administration sectors in Australia, New Zealand, the United Kingdom, and internationally. The company operates through two segments, Wealth Management and Funds Administration. It offers Sonata, a wealth management solution for the administration of a range of wealth management products; Sonata Alta, a digital operating model, which provides clients control over their customer's data, operations, and end customer experiences; Bravura Digital that provides digital service; Garradin, a private wealth and portfolio administration solution for the administration of retail and wholesale wealth management, trusts and estates, SMSFs, managed accounts, fund accounting, and tax; and ePASS, an online portal that provides online services for superannuation members and employers. The company also provides Rufus enterprise solution that offers fund administration for transfer agencies; Rufus SaaS, a transfer agency solution that supports the global administration, servicing, and distribution of a range of investments; Babel solution, a financial messaging platform that connects to a range of financial product distributor platforms and the back-office functions of various markets using message media and formats; taWeb, a digital platform for transfer agents and fund managers; and financial planning solutions, such as AdviceOS and Digital Advice. In addition, it offers professional services, including consulting, data migration and services, software development, support, project management, and training services, as well as managed and cloud services. The company was formerly known as Bravura Solutions Holdings Pty Ltd and changed its name to Bravura Solutions Limited in October 2016. Bravura Solutions Limited was founded in 2004 and is headquartered in Sydney, Australia.

Full BVSFF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BVSFF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVSFF vs SCHDBVSFF vs JEPIBVSFF vs OBVSFF vs KOBVSFF vs MAINBVSFF vs JNJBVSFF vs ABBVBVSFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.